Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

Investigational New Drugs

Volumn 22, Issue 2, 2004, Pages 177-179

  Kondagunta, G Varuni ^a   Bacik, Jennifer ^a   Schwartz, Lawrence ^a   Sheinfeld, Joel ^a   Bajorin, Dean ^a   Vuky, Jacqueline ^a   Marion, Stephanie ^a   Mazumdar, Madhu ^a   Bosl, George J ^a   Motzer, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cisplatin refractory; Germ cell tumor; Nonseminoma; Phase II; Temozolomide

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; TEMOZOLOMIDE; TUMOR MARKER;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GERM CELL TUMOR; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SOLID TUMOR; TERATOCARCINOMA;

ADULT; CISPLATIN; CONFIDENCE INTERVALS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GERMINOMA; HUMANS; MALE; MEDIASTINAL NEOPLASMS; TESTICULAR NEOPLASMS;

EID: 10744223010     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000011794.21608.59     Document Type: Article

References (7)

1. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337: 242-253, 1997
2. Motzer RJ: High-dose chemotherapy for germ cell tumors (GCT): Memorial Sloan-Kettering Cancer Center. Bone Marrow Transplant 18 (Suppl 1): S53-S54, 1996
3. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ: Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559-2563, 1997
4. Loehrer PJ, Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500-2504, 1998
5. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-942, 1993
6. Pera MF, Koberle B, Masters JR: Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br J Cancer 71: 904-906, 1995
7. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13(4): 1961